<!– –> <!– Page Last Updated: 05/24/2013 –> Page Last Updated: 05/24/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use
<!– –> <!– Page Last Updated: 05/15/2013 –> Page Last Updated: 05/15/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
Safety Announcement [05-06-2013]  The U.S. Food and Drug Administration (FDA) is advising health care professionals and women that the anti-seizure medication valproate sodium and related products, valproic acid and divalproex sodium, are contraindicated and should not be taken by pregnant women for the prevention of migraine headaches. Based on information from a recent study, there is evidence…
Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)
<!– –> <!– Page Last Updated: 05/06/2013 –> Page Last Updated: 05/06/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FAERS Quarterly Data Files Documentation
<!– –> <!– Page Last Updated: 05/03/2013 –> Page Last Updated: 05/03/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death
<!– –> <!– Page Last Updated: 04/30/2013 –> Page Last Updated: 04/30/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Funding and Support
<!– –> <!– Page Last Updated: 04/22/2013 –> Page Last Updated: 04/22/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
4th Annual FDA/DIA Statistics Forum: Integrating Knowledge in Clinical Development: Meta-analysis, Non-Inferiority, and Related Topics
<!– –> <!– Page Last Updated: 04/17/2013 –> Page Last Updated: 04/17/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Small Business Education Series
<!– –> <!– Page Last Updated: 04/09/2013 –> Page Last Updated: 04/09/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes
[3-14-2013] The U.S. Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These…